Market Research Logo

Computer-Aided Drug Discovery Services Market, 2018-2030

Computer-Aided Drug Discovery Services Market, 2018-2030

The early stages of research related to drug discovery, including the identification of a relevant biological target and a viable lead compound, play a crucial role in the overall success of a drug candidate in preclinical and clinical studies. It is also worth noting that the process of drug discovery is extremely demanding, both in terms of capital requirements and time. Moreover, there is always a high risk of failure associated with R&D programs and, considering the increasing regulatory stringency, the approval of new drugs has become significantly more difficult.

Given the increase in complexity of the drug discovery process, the overall R&D spending in the pharmaceutical / biotechnology sector has grown from around USD 128 billion in 2008 to USD 158 billion in 2017. As a result, the industry is currently under tremendous pressure not only to meet the expectations of a growing patient population, but also to identify ways to mitigate the risks associated with novel drug discovery programs to avoid failure.

Over the years, various computational tools and services have emerged, enabling the selection, modeling, analysis and optimization of potential lead candidates. The predictive power of computer-aided drug discovery (CADD) has proven to be extremely advantageous, allowing researchers to bypass the random screening of billions of molecules across hundreds of biological targets. As a result, players offering novel in silico drug discovery services, such as CADD, have now become an integral part of the pharmaceutical industry. According to industry experts, almost 30% of the total cost and time invested in developing a new drug can be saved by utilizing such services. Owing to the significant cost benefits offered by such approaches, the adoption of CADD is anticipated to increase in the coming years. Furthermore, the growing number of drug discovery projects, coupled to their rapid progression through various stages of drug discovery, is expected to continue to create an increasing demand for computational services.

SCOPE OF THE REPORT
The ‘Computer-Aided Drug Discovery Services Market, 2018-2030’ report features an extensive study on the current landscape and the likely future potential of the players providing CADD services for drug discovery. The study provides an in-depth analysis, highlighting the capabilities of a diverse set of companies that offer such services across different stages of drug discovery, such as target identification, target validation, hit generation, hit-to-lead and lead optimization. Amongst other elements, the report features:
 An overview of the current market landscape, featuring a comprehensive list of over 120 players that offer CADD services, and detailed analysis based on a number of parameters, such as the location of headquarters, employee count, type of business model used (contract service providers, software / technology providers and consulting service providers), number of drug discovery step(s) for which the company offers CADD services (target identification, target validation, hit generation, hit-to-lead and lead optimization), type of molecule(s) (biologics and small molecules), type of clientele (pharmaceutical / biotechnology companies and academic / research institutes), CADD approach adopted (structure-based drug design, ligand-based drug design and fragment-based drug design) and type of CADD service(s) offered (docking, molecular modeling and virtual screening etc.). In addition, the report features a year-wise analysis of the number of players that have been established over the past three decades.
 An analysis of the most active regions based on the presence of CADD service providers; the report contains a schematic world map representation indicating the geographical location of key hubs with respect to outsourcing activity within this domain.
 A logo landscape of the industry players engaged in this domain, distributed on the basis of the location of their respective headquarters and company size (very small-sized (<10 employees), small-sized (11-50 employees), mid-sized (>50 employees) and large (>200 employees)).
 Elaborate profiles of established players that offer a comprehensive range of CADD services and have received funding in the past two decades. Each profile provides an overview of the company, its financial performance (if available), funding information (if available), information on its CADD specific service(s) portfolio, and a comprehensive future outlook. In addition, each profile features a peer group-based benchmark comparison matrix for the players based on several parameters, such as the number of CADD service(s) offered, number of drug discovery step(s), type of molecule(s), type of clientele and experience of the company.
 Tabulated profiles of emerging players (mid-sized companies or start-ups, established after 2012), featuring details on company headquarters, year of establishment, number of employees, key executives, funding information (if available), CADD service portfolio, CADD technology (if any), key developments related to CADD (if any) and business strategy.
 An analysis of investments made in this domain; these include seed financing, venture capital financing, debt financing, equity crowdfunding and grants / awards received by the companies that are operating in this area.
 An elaborate valuation analysis of companies involved in providing CADD services to the pharmaceutical / biotechnology industry. For this purpose, we have focused only on companies that have received funding in the past two decades and built a multi-variable dependent model to estimate the current valuation of the aforementioned players.
 A detailed analysis of the cost saving potential in the drug discovery process that can be brought about by the adoption of CADD.
 A discussion on the upcoming computational approaches (such as artificial intelligence and cloud computing) that are being adopted for drug discovery and are likely to impact early stage research over the coming years.

One of the key objectives of this report was to evaluate the current opportunity and the future potential of the CADD market over the coming decade. Based on several parameters, we have provided an informed estimate of the likely evolution of this market in the short to mid-term and long term, for the period 2018-2030. In addition, we have provided the likely distribution of the future opportunity based on [A] regional evolution of the market covering key geographies, such as North America (the US and Canada), Europe (Italy, Germany, France, Spain, the UK and rest of Europe), and Asia-Pacific (China, India and Japan), along with the rest of the world, [B] key step(s) of drug discovery (target identification, target validation, hit generation, hit-to-lead and lead optimization), [C] type of molecule(s) (biologics and small molecules), [D] type of sponsor (pharmaceutical / biotechnology companies and academic / research institutes) and [E] therapeutic areas. Considering the uncertainties associated with the growth of CADD market, and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

The opinions and insights presented in this study were influenced by inputs solicited via a comprehensive survey and discussions conducted with several key players in this domain. The report features detailed transcripts of interviews held with Edelmiro Moman (Scientific Consultant and Teacher, ProSciens), John L Kulp (Chief Executive Officer and Chief Technical Officer, Conifer Point Pharmaceuticals), Mark Whittaker (Senior Vice President, Evotec), and Sven Benson (Founder, candidum). All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

EXAMPLE HIGHLIGHTS
1. During our research, we identified over 120 players that are actively involved in providing a wide array of CADD services for drug discovery; lead optimization, hit-to-lead and lead generation are amongst the most popular drug discovery steps for which such services are offered. Around 15 companies offer end-to-end CADD services for drug discovery, starting from target identification to lead optimization. Examples of such one-stop-shops include (in alphabetical order) Allesh Biosciences Labs, CompChem Solutions, Evotec, Gfree Bio, GVK Biosciences, Quantitative Medicine, Sai Life Sciences, Shechter Computational Solutions and SilicsBio.
2. The current market is characterized by the presence of several established, as well as emerging players. Of these, 23% are large companies (more than 200 employees), 15% are mid-sized companies (50-200 employees), while 62% are small-sized players (less than 50 employees). Examples of established players with more than 25 years of experience in the pharmaceutical sector include (in alphabetical order) AMRI, Charles River Laboratories, ChemDiv, Evotec, RTI International, Schrödinger and XRQTC. Some of the new players that have recently entered this domain include (in alphabetical order) ChemBio Discovery Solutions, Discover Drugs, Fractal Therapeutics, Micar Innovation, Nostrum Biodiscovery and NovaData Solutions.
3. Around 80% of the CADD service providers are located in North America and Europe. It is also worth highlighting that there are several such players based in certain emerging regions within Asia Pacific, namely India and China. Examples of some of the large companies based in these locations include (in alphabetical order) ChemPartner, Excelra Knowledge Solutions, GVK Biosciences, Jubilant Biosys, Medicilon, Pharmaron, Sundia MediTech, Syngene, TCG Lifesciences, Viva Biotech and WuXi AppTec.
4. CADD solutions / services have been shown to significantly reduce the cost and time spent in early stage drug discovery. The computation approach is estimated to save as much as 30% of this cost and also enables researchers to expedite the overall process, saving a significant amount of time. By 2030, we anticipate net annual cost savings of over USD 9 billion to be brought about by the adoption of CADD in the drug discovery process.
5. Driven by the rising number of drugs in the discovery stage across various therapeutic areas, the market is expected to continue on its growth trajectory in the foreseen future. We expect the CADD market to grow at an annualized rate of ~12.4% between 2018 and 2030. In terms of therapeutic areas, oncological disorders (46%), neurological disorders (13%), immunological disorders (7%) and infectious diseases (6%) are expected to capture a significant fraction of the market by 2030.
6. Hit and lead related services are expected to possess the largest market share (over 85%) by 2030, followed by target-based services (which include target identification and target validation). Although, the current market is largely driven (over 70%) by small molecules, large molecule drugs are expected to make a relatively larger contribution in the foreseen future; upcoming CADD technologies are likely to provide the necessary impetus to fuel this growth.
7. In terms of geography, majority (~ 70%) of the market share is likely to be distributed between North America and Europe in 2030; other countries, such as China and Japan, are expected to grow at a relatively faster rate (~14%) in the coming decade.

RESEARCH METHODOLOGY
The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.
The secondary sources of information include
 Annual reports
 Investor presentations
 SEC filings
 Industry databases
 News releases from company websites
 Government policy documents
 Industry analysts’ views
While the focus has been on forecasting the market till 2030, the report also provides our independent view on various trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

CHAPTER OUTLINES
Chapter 2 provides an executive summary of the key insights captured in our research. The summary offers a high-level view on the likely evolution of the CADD services market in the short to mid-term and long term.

Chapter 3 provides an introduction to the overall drug discovery process. It includes details on the time taken for a drug to traverse from the bench to the market, along with the historical evolution of CADD. It also provides an overview of CADD, its classification and applications in the drug discovery process. In addition, it provides an in-depth explanation of each step involved in the drug discovery process, along with details on associated CADD specific methods / technologies / approaches. It also highlights the benefits offered by CADD services in the drug discovery process. Further, the chapter features a discussion on the key challenges associated with conducting CADD research in-house, highlighting the evident shift towards outsourcing CADD related operations.

Chapter 4 provides a comprehensive review of the global landscape of the CADD services market. It includes information of over 120 players that are currently engaged in providing such services to the pharmaceutical / biotechnology industry. It features an in-depth market overview, including information on location of headquarters, employee count, type of business model used (contract service providers, software / technology providers and consulting service providers), number of drug discovery step(s) for which the company offers CADD services (target identification, target validation, hit generation, hit-to-lead and lead optimization), type of molecule(s) (biologics and small molecules), type of clientele (pharmaceutical / biotechnology companies and academic / research institutes), CADD approach adopted (structure-based drug design, ligand-based drug design and fragment-based drug design) and type of CADD service(s) offered (docking, molecular modeling and virtual screening etc.). The chapter also provides a list of CADD software / technologies, along with their developers, to represent the overall activity in this field. It also includes an indicative list of players offering CADD consulting services. In addition, the chapter also includes a logo landscape of the players engaged in this domain, distributed on the basis of the location of their respective headquarters and company size.
Chapter 5 features detailed profiles of established CADD service providers based in North America that have received funding in the past two decades. Each profile provides an overview of the company, its financial performance (if available), funding information (if available), information on its CADD specific service(s) portfolio, and a comprehensive future outlook. In addition, each profile features a peer group-based benchmark comparison matrix. The chapter also features tabulated profiles of emerging players based in North America (mid-sized companies or start-ups, established after 2012), featuring details on company headquarters, year of establishment, number of employees, key executives, funding information (if available), CADD service portfolio, CADD technology (if any), key developments related to CADD (if any) and business strategy.

Chapter 6 features detailed profiles of established CADD service providers based in Europe that have received funding in the past two decades. Each profile provides an overview of the company, its financial performance (if available), funding information (if available), information on its CADD specific service(s) portfolio, and a comprehensive future outlook. In addition, each profile features a peer group-based benchmark comparison matrix. The chapter also features tabulated profiles of emerging players based in Europe (mid-sized companies or start-ups, established after 2012), featuring details on company headquarters, year of establishment, number of employees, key executives, funding information (if available), CADD service portfolio, CADD technology (if any), key developments related to CADD (if any) and business strategy.

Chapter 7 features detailed profiles of established CADD service providers based in Asia-Pacific that have received funding in the past two decades. Each profile provides an overview of the company, its financial performance (if available), funding information (if available), information on its CADD specific service(s) portfolio, and a comprehensive future outlook. In addition, each profile features a peer group-based benchmark comparison matrix. The chapter also features tabulated profiles of emerging players based in Asia-Pacific (mid-sized companies or start-ups, established after 2012), featuring details on company headquarters, year of establishment, number of employees, key executives, funding information (if available), CADD service portfolio, CADD technology (if any), key developments related to CADD (if any) and business strategy.

Chapter 8 provides information on various investments and grants received by companies that are engaged in this domain. It includes a detailed analysis of the funding instances that have taken place in the period between 2010 and 2018, highlighting the growing interest of the venture capital community and other strategic investors in this domain.
Chapter 9 features a comprehensive valuation analysis of the companies that are offering CADD services for drug discovery. The chapter provides insights based on a multi-variable dependent valuation model, which is based on the year of establishment, employed workforce, funding received, and the depth of CADD service portfolio.

Chapter 10 presents insights generated from a detailed survey, wherein we invited over 200 stakeholders involved in outsourcing CADD services. The participants, who were primarily Directors / CXO level representatives of their respective companies, helped us develop a deeper understanding on the nature of their services and their associated commercial potential.

Chapter 11 presents a comprehensive analysis of the cost saving potential associated with using CADD in the drug discovery process.

Chapter 12 presents a comprehensive market forecast analysis, highlighting the future potential of the CADD industry till the year 2030. It features the likely distribution of the market based on [A] regional evolution of the market covering key geographies, such as North America (the US and Canada), Europe (Italy, Germany, France, Spain, the UK and rest of Europe), and Asia-Pacific (China, India and Japan), along with the rest of the world, [B] key step(s) of drug discovery (target identification, target validation, hit generation, hit-to-lead and lead optimization), [C] type of molecule(s) (biologics and small molecules), [D] type of sponsor (pharmaceutical / biotechnology companies and academic / research institutes) and [E] therapeutic areas.

Chapter 13 provides a brief overview of the upcoming computational technologies, which are being developed to deal with the innate complexities associated with the process of drug discovery and optimize the overall time spent on early stage research. We believe these novel technologies are likely to have a notable influence on the industry’s evolution over the coming decade.

Chapter 14 is a collection of interview transcripts of discussions held with key stakeholders in this industry. In this chapter, we have presented the details of our conversations held with Edelmiro Moman (Scientific Consultant and Teacher, ProSciens), John L Kulp (Chief Executive Officer and Chief Technical Officer, Conifer Point Pharmaceuticals), Mark Whittaker (Senior Vice President, Evotec), Sven Benson (Founder, candidum).

Chapter 15 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.
Chapter 16 is an appendix, which provides the list of companies and organizations mentioned in the report.

Chapter 17 is an appendix, which features a detailed discussion of the various non-computational techniques that are being adopted for drug discovery and are likely to impact early stage research in the coming years.

LIST OF COMPANIES AND ORGANIZATIONS

The following companies and organizations have been mentioned in the report:

1. Aaranya Biosciences
2. Agilux Laboratories
3. Aisling Capital
4. A-Level Capital
5. Allesh Biosciences Labs
6. Almi Invest
7. AMRI
8. Andy Jennings Consulting
9. APEIRON Biologics
10. Aprecia Pharmaceuticals
11. Aptuit
12. Aquila BioMedical
13. Aragen Bioscience
14. Aris Pharmaceuticals
15. Asahi Kasei Pharma
16. Asclepia MedChem Solutions
17. AstraZeneca
18. ATHOS Service
19. Atlas Ventures
20. Aurora Fine Chemicals
21. Avistron Chemistry Services
22. Banco Santander
23. Bayer
24. BenevolentAI
25. BIANA
26. Bienta
27. BioAscent
28. BioDiscovery Group
29. BioDuro
30. BioGenerator
31. Biognos
32. Bionomics
33. BioNTech
34. BioSolveIT
35. Biotechnology Value Fund
36. Biovista
37. Blue Stream Laboratories
38. BOC Sciences
39. Brains On-Line
40. Broad Institute
41. CAChe Research
42. candidum
43. Carna Biosciences
44. Carrick Therapeutics
45. Cascade Investment
46. Center for the Development of Industrial Technology
47. Celgene
48. Celsis
49. Charles River Laboratories
50. ChemAxon
51. ChemBio Discovery Solutions
52. ChemDiv
53. ChemEnvision
54. Chemical Computing Group
55. ChemModeling
56. ChemoGenics BioPharma
57. Chemotargets
58. ChemPartner
59. China Canada Angels Alliance
60. ChrysCapital
61. CITIC M&A Fund
62. Clearlake Capital Group
63. Cloud Pharmaceuticals
64. CloudScientific
65. Colorado Computational
66. CompChem Solutions
67. Concept Life Sciences
68. Confluence Discovery Technologies
69. Conifer Point Pharmaceuticals
70. Creative Biolabs
71. Creative Biostructure
72. Crelux
73. Cresset
74. Crowdcube
75. CXR Biosciences
76. Cyclica
77. Cyprotex
78. Cystic Fibrosis Foundation
79. DCM Ventures
80. Deep Knowledge Ventures
81. Discover Drugs
82. DIVERCHIM
83. Eagle Pharmaceuticals
84. Edelris
85. Eli Lilly
86. EligoChem
87. Enamine Biology Services
88. Entelos
89. Epic Capital Management
90. Equinox Pharma
91. European Investment Fund
92. Euticals
93. Evotec
94. Excelra Knowledge Solutions
95. Exscientia
96. Fidelity Management & Research Company
97. Fidelta
98. Formex
99. Fractal Therapeutics
100. Galapagos
101. Genedata
102. Genentech
103. Genmab
104. Genomodel
105. Gfree Bio
106. GL Capital
107. GLSynthesis
108. Government of Singapore Investment
109. Greenpharma
110. GreenSky Capital
111. GTCR
112. GVK Biosciences
113. H3 Biomedicine
114. Harvard University
115. HH&E Ventures
116. IBM
117. Icagen
118. Innovate UK
119. Innovative Informatica Technologies
120. Inserm
121. Insilico Medicine
122. Inte:Ligand
123. Invus
124. IOTA Pharmaceuticals
125. Janssen Pharmaceuticals
126. Janus Henderson Investors
127. JPT Peptide Technologies
128. Jubilant Biosys
129. Juno Capital
130. KWS BioTest
131. Laxai Life Sciences
132. Lead Discovery Siena
133. Lead Molecular Design
134. LeadInvent Technologies
135. Legend Capital
136. Liatris Biosciences
137. Life Chemicals
138. Longbow Capital
139. LU Innovation, Lund University
140. Mascot Industries
141. Massachusetts Institute of Technology
142. Medicilon
143. Medisyn Technologies
144. Medit
145. Menarini Group
146. Merck
147. Micar Innovation
148. Michaelson Capital Partners
149. MIG Fonds
150. Mind the Byte
151. Molcode
152. Molecular Cornerstones
153. Molecular Discovery
154. Molecular Forecaster
155. Molsoft
156. Morphic Therapeutics
157. MPI Research
158. Nanosyn
159. National Institutes of Health
160. New England Discovery Partners
161. NiKem Research
162. Nimbus Therapeutics
163. Nodthera
164. Nostrum Biodiscovery
165. NovaData Solutions
166. NovaLead Pharma
167. NovAliX
168. NovaMechanics
169. Novartis
170. Novo Holdings
171. Novo Informatics
172. National Science Foundation
173. NuChem Therapeutics
174. Numerate
175. Oncotest
176. Ono Pharmaceutical
177. OTAVAchemicals
178. Oxford Bioscience Partners
179. Paraza Pharma
180. Pars Silico Bioinformatics Laboratory
181. PathoQuest
182. Peakdale Molecular
183. Petra Pharma
184. Pharma Inventor
185. Pharmacelera
186. Pharmaceutical Product Development
187. Pharmaron
188. Phoenix Equity Partners
189. Porton Pharma Solutions
190. Prestwick Chemical
191. Princeton BioMolecular Research
192. Profacgen
193. Prosarix
194. ProSciens
195. ProtoQSAR
196. Provid Pharmaceuticals
197. ProXyChem
198. Pyxis Discovery
199. Qsol Services India
200. Quantitative Medicine
201. RASA Life Science Informatics
202. Rebexsess Discovery Chemistry
203. Redmile Group
204. Redox Scientific
205. Resource & Environmental Consultants
206. Rosa
207. Rosetta Design Group
208. RTI International
209. Sai Life Sciences
210. Sandexis
211. Sanofi
212. SARomics Biostructures
213. Schrödinger
214. Scientific Analysis Laboratories
215. SciLifeLab
216. Selvita
217. Shechter Computational Solutions
218. Shire
219. SilcsBio
220. Simulations Plus
221. SmiLe Incubator
222. Spectris
223. Startup Health
224. Struengmann Family Office
225. Sundia MediTech
226. Sygnature Discovery
227. Syngene
228. Synsight
229. Taros Chemicals
230. TCG Lifesciences
231. The Carlyle Group
232. Leukemia and Lymphoma Society
233. Tri-Institutional Therapeutics Discovery Institute
234. True PharmaChem
235. Uni-Innovation Group
236. University College London
237. Van Drie Research
238. Victrix Computational and Medicinal Chemistry Consultancy
239. Vipergen
240. Virtua Drug
241. Viva Biotech
242. VLife Sciences Technologies
243. VLS 3D
244. Wellcome Trust
245. WIL Research Laboratories
246. Wildcard Pharmaceutical Consulting
247. Wilmington PharmaTech
248. WuXi AppTec
249. Wyss Institute
250. XRQTC
251. XtalPi
252. ZoBio
253. Zorilla Research


1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Drug Discovery and Development Timeline
3.3. An Overview of CADD
3.3.1. Historical Evolution of CADD in the Drug Discovery Process
3.3.2. Comparison of Traditional Drug Discovery Approaches and CADD
3.3.3. Classification of CADD
3.4. Applications of CADD in the Drug Discovery Process
3.4.1. Target Identification
3.4.1.1. Chemoinformatic Tools
3.4.1.2. Network Based Drug Discovery
3.4.1.3. Computational Platforms and Interaction Repository
3.4.2. Target Validation
3.4.3. Hit Generation
3.4.3.1. High-Throughput Screening
3.4.3.2. Fragment Based Screening
3.4.3.3. Virtual Screening
3.4.4. Hit-to-Lead
3.4.4.1. Pharmacodynamics and Pharmacokinetics Modeling
3.4.4.2. Other Approaches
3.4.5. Lead Optimization
3.4.5.1. Pharmacophore Modeling
3.4.5.2. Docking
3.4.5.3. SAR / QSAR
3.4.5.4. Molecular Modeling
3.5. Advantages of CADD in the Drug Discovery Process
3.6. Challenges Associated with In-House CADD Operations
3.7. Shift in Trend Towards Outsourcing of CADD Operations
3.8. Concluding Remarks
4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. CADD Service Providers: List of Industry Players
4.2.1. Distribution by Year of Establishment
4.2.2. Distribution by Geographical Location
4.2.3. Distribution by Company Size
4.2.4. Distribution by Type of Business Model
4.2.5. Distribution by Drug Discovery Steps
4.2.6. Distribution by Type of Molecule
4.2.7. Distribution by Type of Clientele
4.2.8. Distribution by Type of CADD Approaches
4.2.9. Distribution by Type of CADD Service Offering
4.2.10. Distribution by Company Size and Location of Headquarters
4.3. CADD: List of CADD Software / Technologies
4.4. CADD: List of Consulting Service Providers
5. COMPANY PROFILES: NORTH AMERICA
5.1. Chapter Overview
5.2. Established Players
5.2.1. Albany Molecular Research (AMRI)
5.2.1.1. Company Snapshot
5.2.1.2. Financial Information
5.2.1.3. Funding and Investment Information
5.2.1.4. CADD Service Portfolio
5.2.1.5. Recent Developments and Future Outlook
5.2.1.6. Company Benchmarking Output
5.2.2. BioDuro
5.2.2.1. Company Snapshot
5.2.2.2. Funding and Investment Information
5.2.2.3. CADD Service Portfolio
5.2.2.4. Recent Developments and Future Outlook
5.2.2.5. Company Benchmarking Output
5.2.3. Charles River Laboratories
5.2.3.1. Company Snapshot
5.2.3.2. Financial Information
5.2.3.3. Funding and Investment Information
5.2.3.4. CADD Service Portfolio
5.2.3.5. Recent Developments and Future Outlook
5.2.3.6. Company Benchmarking Output
5.2.4. Schrödinger
5.2.4.1. Company Snapshot
5.2.4.2. Funding and Investment Information
5.2.4.3. CADD Service Portfolio
5.2.4.4. Recent Developments and Future Outlook
5.2.4.5. Company Benchmarking Output
5.3. Emerging Players
5.3.1. ChemBio Discovery Solutions
5.3.2. Colorado Computational
5.3.3. Conifer Point Pharmaceuticals
5.3.4. Cyclica
5.3.5. Fractal Therapeutics
5.3.6. Insilico Medicine
5.3.7. Shechter Computational Solutions
5.3.8. Quantitative Medicine
5.3.9. Zorilla Research
6. COMPANY PROFILES: EUROPE
6.1. Chapter Overview
6.2. Established Players
6.2.1. BioNTech
6.2.1.1. Company Snapshot
6.2.1.2. Funding and Investment Information
6.2.1.3. CADD Service Portfolio
6.2.1.4. Recent Developments and Future Outlook
6.2.1.5. Company Benchmarking Output
6.2.2. Concept Life Sciences
6.2.2.1. Company Snapshot
6.2.2.2. Funding and Investment Information
6.2.2.3. CADD Service Portfolio
6.2.2.4. Recent Developments and Future Outlook
6.2.2.5. Company Benchmarking Output
6.2.3. Evotec
6.2.3.1. Company Snapshot
6.2.3.2. Financial Information
6.2.3.3. Funding and Investment Information
6.2.3.4. CADD Service Portfolio
6.2.3.5. Recent Developments and Future Outlook
6.2.3.6. Company Benchmarking Output
6.2.4. Selvita
6.2.4.1. Company Snapshot
6.2.4.2. Financial Information
6.2.4.3. Funding and Investment Information
6.2.4.4. CADD Service Portfolio
6.2.4.5. Recent Developments and Future Outlook
6.2.4.6. Company Benchmarking Output
6.2.5. Sygnature Discovery
6.2.5.1. Company Snapshot
6.2.5.2. Funding and Investment Information
6.2.5.3. CADD Service Portfolio
6.2.5.4. Recent Developments and Future Outlook
6.2.5.5. Company Benchmarking Output
6.3. Emerging Players
6.3.1. BioAscent
6.3.2. candidum
6.3.3. Fidelta (A Subsidiary of Galapagos)
6.3.4. Genomodel
6.3.5. Micar Innovation
6.3.6. Nostrum Biodiscovery
6.3.7. NovaData Solutions
6.3.8. Synsight
7. COMPANY PROFILES: ASIA-PACIFIC
7.1. Chapter Overview
7.2. Established Players
7.2.1. GVK Biosciences
7.2.1.1. Company Snapshot
7.2.1.2. Financial Information
7.2.1.3. Funding and Investment Information
7.2.1.4. CADD Service Portfolio
7.2.1.5. Recent Developments and Future Outlook
7.2.1.6. Company Benchmarking Output
7.2.2. Pharmaron
7.2.2.1. Company Snapshot
7.2.2.2. Funding and Investment Information
7.2.2.3. CADD Service Portfolio
7.2.2.4. Recent Developments and Future Outlook
7.2.2.5. Company Benchmarking Output
7.2.3. Sundia MediTech
7.2.3.1. Company Snapshot
7.2.3.2. Funding and Investment Information
7.2.3.3. CADD Service Portfolio
7.2.3.4. Recent Developments and Future Outlook
7.2.3.5. Company Benchmarking Output
7.2.4. WuXi AppTec
7.2.4.1. Company Snapshot
7.2.4.2. Financial Information
7.2.4.3. Funding and Investment Information
7.2.4.4. CADD Service Portfolio
7.2.4.5. Recent Developments and Future Outlook
7.2.4.6. Company Benchmarking Output
7.3. Emerging Players
7.3.1. Aaranya Biosciences
7.3.2. Discover Drugs
8. FUNDING AND INVESTMENT ANALYSIS
8.1. Chapter Overview
8.2. Types of Funding
8.3. CADD Service Providers: Funding and Investment Analysis
8.3.1. Analysis by Cumulative Number of Funding Instances
8.3.2. Analysis by Amount Invested
8.3.3. Analysis by Type of Funding
8.3.4. Analysis by Most Active Players
8.3.5. Analysis by Most Active Investors
8.4. Concluding Remarks
9. COMPANY VALUATION ANALYSIS
9.1. Chapter Overview
9.2. Company Valuation Analysis: Methodology
9.3. Company Valuation Analysis: Categorization by Multiple Parameters
9.3.1. Categorization by Employee Count
9.3.2. Categorization by Google Hits
9.3.3. Categorization by Weighted Average Score
9.3.4. Company Valuation: Roots Analysis Proprietary Scores
10. SURVEY ANALYSIS
10.1. Chapter Overview
10.2. Overview of Respondents
10.3. Drug Discovery Steps
10.4. Type of Molecules
10.5. CADD Service Portfolio
10.6. Current Market Opportunity
10.7. Likely Growth Rate
10.8. Cost and Time Reduction using CADD
11. COST SAVING ANALYSIS
11.1. Chapter Overview
11.2. Key Assumptions
11.3. Methodology
11.4. Overall Cost Saving by using CADD, 2018-2030
11.5. Concluding Remarks
12. MARKET FORECAST
12.1. Chapter Overview
12.2. Forecast Methodology and Key Assumptions
12.3. Overall CADD Market, 2018-2030
12.4. CADD Market, 2018-2030: Distribution by Regions
12.4.1. CADD Market in North America, 2018-2030
12.4.1.1. CADD Market in the US, 2018-2030
12.4.1.2. CADD Market in Canada, 2018-2030
12.4.2. CADD Market in Europe, 2018-2030
12.4.2.1. CADD Market in Germany, 2018-2030
12.4.2.2. CADD Market in France, 2018-2030
12.4.2.3. CADD Market in the UK, 2018-2030
12.4.2.4. CADD Market in Italy, 2018-2030
12.4.2.5. CADD Market in Spain, 2018-2030
12.4.2.6. CADD Market in Rest of Europe, 2018-2030
12.4.3. CADD Market in Asia-Pacific and Rest of the World, 2018-2030
12.4.3.1. CADD Market in Japan, 2018-2030
12.4.3.2. CADD Market in China, 2018-2028
12.4.3.3. CADD Market in India, 2018-2030
12.4.3.4. CADD Market in Rest of the World, 2018-2030
12.5. CADD Market, 2018-2030: Distribution by Drug Discovery Steps
12.5.1. CADD Market for Target Identification, 2018-2030
12.5.2. CADD Market for Target Validation, 2018-2030
12.5.3. CADD Market for Hit Generation, 2018-2030
12.5.4. CADD Market for Hit-to-Lead, 2018-2030
12.5.5. CADD Market for Lead Optimization, 2018-2030
12.6. CADD Market, 2018-2030: Distribution by Type of Molecule
12.6.1. CADD Market for Small Molecules, 2018-2030
12.6.2. CADD Market for Biologics, 2018-2030
12.7. CADD Market, 2018-2030: Distribution by Therapeutic Areas
12.7.1. CADD Market for Blood Disorders, 2018-2030
12.7.2. CADD Market for Cardiovascular Disorders, 2018-2030
12.7.3. CADD Market for Gastrointestinal and Digestive Disorders, 2018-2030
12.7.4. CADD Market for Hormonal Disorders, 2018-2030
12.7.5. CADD Market for Infectious Diseases, 2018-2030
12.7.6. CADD Market for Immunological Disorders, 2018-2030
12.7.7. CADD Market for Mental Disorders, 2018-2030
12.7.8. CADD Market for Metabolic Disorders, 2018-2030
12.7.9. CADD Market for Neurological Disorders, 2018-2030
12.7.10. CADD Market for Oncological Disorders, 2018-2030
12.7.11. CADD Market for Respiratory Disorders, 2018-2030
12.7.12. CADD Market for Skin Disorders, 2018-2030
12.7.13. CADD Market for Urogenital Disorders, 2018-2030
12.7.14. CADD Market for Other Disorders, 2018-2030
12.7.15. CADD Market, 2018-2030: Market Attractiveness Analysis by Therapeutic Areas
12.8. CADD Market, 2018-2030: Distribution by Type of Sponsor
12.8.1. CADD Market for Industry Players, 2018-2030
12.8.2. CADD Market for Non-Industry Players, 2018-2030
12.9. Concluding Remarks
13. CADD AND FUTURE TRENDS IN DRUG DISCOVERY
13.1. Chapter Overview
13.2. Owing to Potential Cost and Time Benefits, Outsourcing of Drug Discovery Operations is Expected to Increase in the Future
13.3. Technological Advancements are Likely to Revolutionize the Current Drug Discovery Processes
13.3.1. Integration of Artificial Intelligence in Drug Discovery is Expected to Improve the Overall Efficiency and Productivity
13.3.2. Increased Adoption of Cloud Based Technology Platforms is Expected to Improve the Scalability and Flexibility of Drug Discovery Processes
13.4. Concluding Remarks
14. EXECUTIVE INSIGHTS
14.1. Chapter Overview
14.2. ProSciens
14.2.1. Company Snapshot
14.2.2. Interview Transcript: Edelmiro Moman, Founder and Chief Executive Officer
14.3. Conifer Point Pharmaceuticals
14.3.1. Company Snapshot
14.3.2. Interview Transcript: John L Kulp, Chief Executive Officer and Chief Technical Officer
14.4. Evotec
14.4.1. Company Snapshot
14.4.2. Interview Transcript: Mark Whittaker, Senior Vice President, Drug Discovery
14.5. candidum
14.5.1. Company Snapshot
14.5.2. Interview Transcript: Sven Benson, Founder
15. APPENDIX 1: TABULATED DATA
16. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
17. APPENDIX 3: NON-COMPUTATIONAL METHODS FOR DRUG DISCOVERY 
LIST OF FIGURES
Figure 3.1 Drug Discovery and Development Timeline
Figure 3.2 Historical Evolution of Computational Drug Discovery Approaches
Figure 3.3 Steps Involved in Virtual Drug Discovery Process
Figure 3.4 Comparison of Traditional Drug Discovery Approaches and CADD
Figure 3.5 Classification of CADD Approaches
Figure 3.6 CADD Service Map for Drug Discovery Process
Figure 3.7 Advantages of using CADD in Drug Discovery Process
Figure 4.1 CADD Service Providers: Cumulative Number of Companies by Year of Establishment
Figure 4.2 CADD Service Providers: Distribution by Geographical Location
Figure 4.3 CADD Service Providers: Distribution by Countries
Figure 4.4 CADD Service Providers: Distribution by Company Size
Figure 4.5 CADD Service Providers: Distribution by Type of Business Model
Figure 4.6 CADD Service Providers: Distribution by Drug Discovery Steps
Figure 4.7 CADD Service Providers: Distribution by Type of Molecule
Figure 4.8 CADD Service Providers: Distribution by Type of Clientele
Figure 4.9 CADD Service Providers: Distribution by CADD Approaches
Figure 4.10 CADD Service Providers: Distribution by CADD Service Offering
Figure 4.11 CADD Service Providers Logo Landscape: Distribution by Company Size and Location of Headquarters
Figure 5.1 AMRI: Annual Revenues, 2012-Q1 2017 (USD Million)
Figure 5.2 AMRI: Contract Revenues by Business Segments, 2012-2016 (USD Million)
Figure 5.3 AMRI: CADD Service Portfolio
Figure 5.4 AMRI: Company Benchmarking Output
Figure 5.5 BioDuro: CADD Service Portfolio
Figure 5.6 BioDuro: Company Benchmarking Output
Figure 5.7 Charles River Laboratories: Business Segments
Figure 5.8 Charles River Laboratories: Revenues, 2013–Q1 2018 (USD Billion)
Figure 5.9 Charles River Laboratories: CADD Service Portfolio
Figure 5.10 Charles River Laboratories: Company Benchmarking Output
Figure 5.11 Schrödinger: CADD Service Portfolio
Figure 5.12 Schrödinger: CADD Software Suites and Packages
Figure 5.13 Schrödinger: Company Benchmarking Output
Figure 6.1 BioNTech: CADD Service Portfolio
Figure 6.2 BioNTech: Company Benchmarking Output
Figure 6.3 Concept Life Sciences: Company Benchmarking Output
Figure 6.4 Evotec: Revenues, 2013-Q1 2018 (EUR Million)
Figure 6.5 Evotec: Revenues by Business Divisions, 2017 (EUR Million)
Figure 6.6 Evotec: Drug Discovery Services
Figure 6.7 Evotec: CADD Service Portfolio
Figure 6.8 Evotec: Company Benchmarking Output
Figure 6.9 Selvita: Revenues, 2013-Q1 2018 (USD Million)
Figure 6.10 Selvita: CADD Service Portfolio
Figure 6.11 Selvita: Company Benchmarking Output
Figure 6.12 Sygnature Discovery: CADD Service Portfolio
Figure 6.13 Sygnature Discovery: Company Benchmarking Output
Figure 7.1 GVK Biosciences: Key Operating Segments
Figure 7.2 GVK Biosciences: CADD Service Portfolio
Figure 7.3 GVK Biosciences: Company Benchmarking Output
Figure 7.4 Pharmaron: CADD Service Portfolio
Figure 7.5 Pharmaron: Company Benchmarking Output
Figure 7.6 Sundia MediTech: CADD Service Portfolio
Figure 7.7 Sundia MediTech: Company Benchmarking Output
Figure 7.8 WuXi AppTec: Annual Revenues (USD Million)
Figure 7.9 WuXi AppTec: CADD Service Portfolio
Figure 7.10 WuXi AppTec: Company Benchmarking Output
Figure 8.1 CADD Service Providers: Cumulative Number of Funding Instances, 2010-2018
Figure 8.2 CADD Service Providers: Cumulative Amount Invested, 2010-2018 (USD Million)
Figure 8.3 CADD Service Providers: Distribution by Type of Funding, 2010-2018
Figure 8.4 CADD Service Providers: Distribution by Total Amount Invested and Type of Funding, 2010-2018 (USD Million)
Figure 8.5 CADD Service Providers: Most Active Players by Number of Instances, 2010-2018
Figure 8.6 CADD Service Providers: Most Active Players by Amount Invested, 2010-2018
Figure 8.7 CADD Service Providers: Most Active Investors by Number of Instances, 2010-2018
Figure 8.8 CADD Service Providers: Funding and Investment Summary
Figure 9.1 Company Valuation Analysis: A/Y Ratio, Input Dataset
Figure 9.2 Company Valuation Analysis: A/E Ratio, Input Dataset
Figure 9.3 Company Valuation Analysis: A/G Ratio, Input Dataset
Figure 9.4 Company Valuation Analysis: Categorization by Employee Count Score
Figure 9.5 Company Valuation Analysis: Categorization by Google Hits Score
Figure 9.6 Company Valuation Analysis: Categorization by Weighted Average Score
Figure 9.7 Company Valuation Analysis: High Value Players in CADD Industry
Figure 10.1 Survey Analysis: Distribution by Type of Company
Figure 10.2 Survey Analysis: Distribution by Location of Respondents
Figure 10.3 Survey Analysis: Distribution by Seniority Level of Respondents
Figure 10.4 Survey Analysis: Distribution by Drug Discovery Steps
Figure 10.5 Survey Analysis: Distribution by Type of Molecule
Figure 10.6 Survey Analysis: Distribution by CADD Service Portfolio
Figure 10.7 Survey Analysis: Distribution by Current Market Opportunity
Figure 10.8 Survey Analysis: Distribution by Likely Growth Rate
Figure 10.9 Survey Analysis: Distribution by Cost and Time Reduction using CADD
Figure 11.1 Approval Trend for Small Molecule and Large Molecule Drugs: Historical Data (2005-2017)
Figure 11.2 Overall Cost Saving by using CADD: Likely Scenarios
Figure 11.3 Overall Cost Saving by using CADD, 2018-2030 (USD Billion)
Figure 12.1 Overall CADD Market, 2018-2030: Base Scenario (USD Million)
Figure 12.2 CADD Market, 2018-2030: Distribution by Regions, Base Scenario (USD Million)
Figure 12.3 CADD Market, 2018-2030: North America, Base Scenario (USD Million)
Figure 12.4 CADD Market, 2018-2030: US, Base Scenario (USD Million)
Figure 12.5 CADD Market, 2018-2030: Canada, Base Scenario (USD Million)
Figure 12.6 CADD Market, 2018-2030: Europe, Base Scenario (USD Million)
Figure 12.7 CADD Market, 2018-2030: Germany, Base Scenario (USD Million)
Figure 12.8 CADD Market, 2018-2030: France, Base Scenario (USD Million)
Figure 12.9 CADD Market, 2018-2030: UK, Base Scenario (USD Million)
Figure 12.10 CADD Market, 2018-2030: Italy, Base Scenario (USD Million)
Figure 12.11 CADD Market, 2018-2030: Spain, Base Scenario (USD Million)
Figure 12.12 CADD Market, 2018-2030: Rest of Europe, Base Scenario (USD Million)
Figure 12.13 CADD Market, 2018-2030: Asia-Pacific and Rest of the World, Base Scenario (USD Million)
Figure 12.14 CADD Market, 2018-2030: Japan, Base Scenario (USD Million)
Figure 12.15 CADD Market, 2018-2030: China, Base Scenario (USD Million)
Figure 12.16 CADD Market, 2018-2030: India, Base Scenario (USD Million)
Figure 12.17 CADD Market, 2018-2030: Rest of the World, Base Scenario (USD Million)
Figure 12.18 CADD Market, 2018-2030: Distribution by Drug Discovery Steps, Base Scenario (USD Million)
Figure 12.19 CADD Market for Target Identification, 2018-2030: Base Scenario (USD Million)
Figure 12.20 CADD Market for Target Validation, 2018-2030: Base Scenario (USD Million)
Figure 12.21 CADD Market for Hit Generation, 2018-2030: Base Scenario (USD Million)
Figure 12.22 CADD Market for Hit-to-Lead, 2018-2030: Base Scenario (USD Million)
Figure 12.23 CADD Market for Lead Optimization, 2018-2030: Base Scenario (USD Million)
Figure 12.24 CADD Market, 2018-2030: Distribution by Type of Molecule, Base Scenario (USD Million)
Figure 12.25 CADD Market for Small Molecules, 2018-2030: Base Scenario (USD Million)
Figure 12.26 CADD Market for Biologics, 2018-2030: Base Scenario (USD Million)
Figure 12.27 CADD Market for Blood Disorders, 2018-2030: Base Scenario (USD Million)
Figure 12.28 CADD Market for Cardiovascular Disorders, 2018-2030: Base Scenario (USD Million)
Figure 12.29 CADD Market for Gastrointestinal and Digestive Disorders, 2018-2030: Base Scenario (USD Million)
Figure 12.30 CADD Market for Hormonal Disorders, 2018-2030: Base Scenario (USD Million)
Figure 12.31 CADD Market for Infectious Diseases, 2018-2030: Base Scenario (USD Million)
Figure 12.32 CADD Market for Immunological Disorders, 2018-2030: Base Scenario (USD Million)
Figure 12.33 CADD Market for Mental Disorders, 2018-2030: Base Scenario (USD Million)
Figure 12.34 CADD Market for Metabolic Disorders, 2018-2030: Base Scenario (USD Million)
Figure 12.35 CADD Market for Neurological Disorders, 2018-2030: Base Scenario (USD Million)
Figure 12.36 CADD Market for Oncological Disorders, 2018-2030: Base Scenario (USD Million)
Figure 12.37 CADD Market for Respiratory Disorders, 2018-2030: Base Scenario (USD Million)
Figure 12.38 CADD Market for Skin Disorders, 2018-2030: Base Scenario (USD Million)
Figure 12.39 CADD Market for Urogenital Disorders, 2018-2030: Base Scenario (USD Million)
Figure 12.40 CADD Market for Other Disorders, 2018-2030: Base Scenario (USD Million)
Figure 12.41 CADD Market, 2018-2030: Market Attractiveness by Therapeutic Areas, Base Scenario (USD Million)
Figure 12.42 CADD Market, 2018-2030: Distribution by Type of Sponsors, Base Scenario (USD Million)
Figure 12.43 CADD Market for Industry Players, 2018-2030: Base Scenario (USD Million)
Figure 12.44 CADD Market for Non-Industry Players, 2018-2030: Base Scenario (USD Million)
Figure 12.45 Overall CADD Market: Comparative Evolution Scenarios, 2018, 2024 and 2030 (USD Million)
Figure 13.1 Upcoming Trends in Drug Discovery: Future Growth Opportunities
LIST OF TABLES
Table 4.1 CADD Service Providers: List of Industry Players
Table 4.2 CADD Service Providers: Information on Drug Discovery Steps
Table 4.3 CADD Service Providers: Information on Type of Molecule
Table 4.4 CADD Service Providers: Information on Type of Clientele
Table 4.5 CADD Service Providers: Information on CADD Approaches
Table 4.6 CADD Service Providers: Information on CADD Service Offering
Table 4.7 CADD: List of CADD Software / Technologies
Table 4.8 CADD: List of Consulting Service Providers
Table 5.1 CADD Service Providers in North America: List of Companies Profiled
Table 5.2 AMRI: Key Highlights
Table 5.3 AMRI: List of Funding Instances and Investors
Table 5.4 AMRI: Future Outlook
Table 5.5 BioDuro: Key Highlights
Table 5.6 BioDuro: List of Funding Instances and Investors
Table 5.7 BioDuro: Future Outlook
Table 5.8 Charles River Laboratories: Key Highlights
Table 5.9 Charles River Laboratories: List of Funding Instances and Investors
Table 5.10 Charles River Laboratories: Future Outlook
Table 5.11 Schrödinger: Key Highlights
Table 5.12 Schrödinger: List of Funding Instances and Investors
Table 5.13 Schrödinger: Future Outlook
Table 5.14 Company Profile: ChemBio Discovery Solutions
Table 5.15 Company Profile: Colorado Computational
Table 5.16 Company Profile: Conifer Point Pharmaceuticals
Table 5.17 Company Profile: Cyclica
Table 5.18 Company Profile: Fractal Therapeutics
Table 5.19 Company Profile: Insilico Medicine
Table 5.20 Company Profile: Shechter Computational Solutions
Table 5.21 Company Profile: Quantitative Medicine
Table 5.22 Company Profile: Zorilla Research
Table 6.1 CADD Service Providers in Europe: List of Companies Profiled
Table 6.2 BioNTech: Key Highlights
Table 6.3 BioNTech: List of Funding Instances and Investors
Table 6.4 BioNTech: Future Outlook
Table 6.5 Concept Life Sciences: Key Highlights
Table 6.6 Spectris: List of Funding Instances and Investors
Table 6.7 Concept Life Sciences: Future Outlook
Table 6.8 Evotec: Key Highlights
Table 6.9 Evotec: List of Funding Instances and Investors
Table 6.10 Evotec: Future Outlook
Table 6.11 Selvita: Key Highlights
Table 6.12 Selvita: List of Funding Instances and Investors
Table 6.13 Selvita: Future Outlook
Table 6.14 Sygnature Discovery: Key Highlights
Table 6.15 Sygnature Discovery: List of Funding Instances and Investors
Table 6.16 Sygnature Discovery: Future Outlook
Table 6.17 Company Profile: BioAscent
Table 6.18 Company Profile: candidum
Table 6.19 Company Profile: Fidelta
Table 6.20 Company Profile: Genomodel
Table 6.21 Company Profile: Micar Innovation
Table 6.22 Company Profile: Nostrum Biodiscovery
Table 6.23 Company Profile: NovaData Solutions
Table 6.24 Company Profile: Synsight
Table 7.1 CADD Service Providers in Asia-Pacific: List of Companies Profiled
Table 7.2 GVK Biosciences: Key Highlights
Table 7.3 GVK Biosciences: List of Funding Instances and Investors
Table 7.4 GVK Biosciences: Future Outlook
Table 7.5 Pharmaron: Key Highlights
Table 7.6 Pharmaron: List of Funding Instances and Investors
Table 7.7 Pharmaron: Future Outlook
Table 7.8 Sundia MediTech: Key Highlights
Table 7.9 Sundia MediTech: List of Funding Instances and Investors
Table 7.10 Sundia MediTech: Future Outlook
Table 7.11 WuXi AppTec: Key Highlights
Table 7.12 WuXi AppTec: List of Funding Instances and Investors
Table 7.13 WuXi AppTec: Future Outlook
Table 7.14 Company Profile: Aaranya Biosciences
Table 7.15 Company Profile: Discover Drugs
Table 8.1 CADD Service Providers: Funding and Investments, 1999-2018
Table 8.2 CADD Service Providers: Summary of Investments
Table 9.1 Company Valuation Analysis: Sample Dataset
Table 9.2 Company Valuation Analysis: Weighted Average Evaluation
Table 9.3 Company Valuation Analysis: Estimated Valuation
Table 10.1 Survey Response: Overview of the Participating Companies
Table 10.2 Survey Response: Overview of Respondents
Table 10.3 Survey Response: Drug Discovery Steps
Table 10.4 Survey Response: Type of Molecules
Table 10.5 Survey Response: CADD Service Portfolio
Table 10.6 Survey Response: Current Market Opportunity
Table 10.7 Survey Response: Likely Growth Rate
Table 10.8 Survey Response: Cost and Time Reduction using CADD
Table 11.1 Likely Cost Reduction using CADD: Data from Survey Responses
Table 11.2 Drug Discovery Steps: Key Parameters
Table 13.1 Companies Offering Artificial Intelligence and CADD Services
Table 13.2 Companies Offering Cloud Computing Platforms and CADD Services
Table 14.1 ProSciens: Key Highlights
Table 15.1 CADD Service Providers: Cumulative Number of Companies by Year of Establishment
Table 15.2 CADD Service Providers: Distribution by Geographical Location
Table 15.3 CADD Service Providers: Distribution by Company Size
Table 15.4 CADD Service Providers: Distribution by Type of Business Model
Table 15.5 CADD Service Providers: Distribution by Drug Discovery Steps
Table 15.6 CADD Service Providers: Distribution by Type of Molecule
Table 15.7 CADD Service Providers: Distribution by Type of Clientele
Table 15.8 CADD Service Providers: Distribution by CADD Approaches
Table 15.9 CADD Service Providers: Distribution by CADD Service Offering
Table 15.10 AMRI: Annual Revenues, 2012-Q1 2017 (USD Million)
Table 15.11 AMRI: Contract Revenues by Business Segments, 2012-2016 (USD Million)
Table 15.12 Charles River Laboratories: Revenues, 2013-Q1 2018 (USD Billion)
Table 15.13 Evotec: Revenues, 2013-Q1 2018 (EUR Million)
Table 15.14 Evotec: Revenues by Business Divisions, 2017 (EUR Million)
Table 15.15 Selvita: Revenues, 2013-Q1 2018 (USD Million)
Table 15.16 WuXi AppTec: Annual Revenues (USD Million)
Table 15.17 CADD Service Providers: Cumulative Number of Funding Instances, 2010-2018
Table 15.18 CADD Service Providers: Cumulative Amount Invested, 2010-2018 (USD Million)
Table 15.19 CADD Service Providers: Distribution by Type of Funding, 2010-2018 (USD Million)
Table 15.20 CADD Service Providers: Distribution by Total Amount Invested and Type of Funding, 2010-2018 (USD Million)
Table 15.21 CADD Service Providers: Most Active Players by Number of Instances, 2010-2018
Table 15.22 CADD Service Providers: Most Active Players by Amount Invested, 2010-2018
Table 15.23 CADD Service Providers: Most Active Investors by Number of Instances, 2010-2018
Table 15.24 Company Valuation Analysis: A/Y Ratio, Input Dataset
Table 15.25 Company Valuation Analysis: A/E Ratio, Input Dataset
Table 15.26 Company Valuation Analysis: A/G Ratio, Input Dataset
Table 15.27 Survey Analysis: Distribution by Type of Company
Table 15.28 Survey Analysis: Distribution by Location of Respondents
Table 15.29 Survey Analysis: Distribution by Seniority Level of Respondents
Table 15.30 Survey Analysis: Distribution by Drug Discovery Steps
Table 15.31 Survey Analysis: Distribution by Type of Molecule
Table 15.32 Survey Analysis: Distribution by CADD Service Portfolio
Table 15.33 Survey Analysis: Distribution by Current Market Opportunity
Table 15.34 Survey Analysis: Distribution by Likely Growth Rate
Table 15.35 Survey Analysis: Distribution by Cost and Time Reduction using CADD
Table 15.36 Approved Small Molecules and Large Molecules: Historical Trend (2005-2017)
Table 15.37 Overall Cost Saving by using CADD, 2018-2030 (USD Billion)
Table 15.38 Overall CADD Market, 2018-2030: Conservative Scenario (USD Million)
Table 15.39 Overall CADD Market, 2018-2030: Base Scenario (USD Million)
Table 15.40 Overall CADD Market, 2018-2030: Optimistic Scenario (USD Million)
Table 15.41 CADD Market, 2018-2030: Distribution by Regions, Conservative Scenario (USD Million)
Table 15.42 CADD Market, 2018-2030: Distribution by Regions, Base Scenario (USD Million)
Table 15.43 CADD Market, 2018-2030: Distribution by Regions, Optimistic Scenario (USD Million)
Table 15.44 CADD Market, 2018-2030: North America, Conservative Scenario (USD Million)
Table 15.45 CADD Market, 2018-2030: North America, Base Scenario (USD Million)
Table 15.46 CADD Market, 2018-2030: North America, Optimistic Scenario (USD Million)
Table 15.47 CADD Market, 2018-2030: Europe, Conservative Scenario (USD Million)
Table 15.48 CADD Market, 2018-2030: Europe, Base Scenario (USD Million)
Table 15.49 CADD Market, 2018-2030: Europe, Optimistic Scenario (USD Million)
Table 15.50 CADD Market, 2018-2030: Asia-Pacific and Rest of the World, Conservative Scenario (USD Million)
Table 15.51 CADD Market, 2018-2030: Asia-Pacific and Rest of the World, Base Scenario (USD Million)
Table 15.52 CADD Market, 2018-2030: Asia-Pacific and Rest of the World, Optimistic Scenario (USD Million)
Table 15.53 CADD Market, 2018-2030: Distribution by Drug Discovery Steps, Conservative Scenario (USD Million)
Table 15.54 CADD Market, 2018-2030: Distribution by Drug Discovery Steps, Base Scenario (USD Million)
Table 15.55 CADD Market, 2018-2030: Distribution by Drug Discovery Steps, Optimistic Scenario (USD Million)
Table 15.56 CADD Market, 2018-2030: Distribution by Type of Molecule, Conservative Scenario (USD Million)
Table 15.57 CADD Market, 2018-2030: Distribution by Type of Molecule, Base Scenario (USD Million)
Table 15.58 CADD Market, 2018-2030: Distribution by Type of Molecule, Optimistic Scenario (USD Million)
Table 15.59 CADD Market, 2018-2030: Distribution by Therapeutic Areas, Conservative Scenario (USD Million)
Table 15.60 CADD Market, 2018-2030: Distribution by Therapeutic Areas, Base Scenario (USD Million)
Table 15.61 CADD Market, 2018-2030: Distribution by Therapeutic Areas, Optimistic Scenario (USD Million)
Table 15.62 CADD Market, 2018-2030: Market Attractiveness Analysis by Therapeutic Areas (USD Million)
Table 15.63 CADD Market, 2018-2030: Distribution by Type of Sponsors, Conservative Scenario (USD Million)
Table 15.64 CADD Market, 2018-2030: Distribution by Type of Sponsors, Base Scenario (USD Million)
Table 15.65 CADD Market, 2018-2030: Distribution by Type of Sponsors, Optimistic Scenario (USD Million)
Table 15.66 Overall CADD Market: Comparative Evolution Scenarios, 2018, 2024 and 2030 (USD Million)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report